Science Current Events | Science News | Brightsurf.com
 

FDG-PET Imaging Clearly Predicts Lung Cancer Patients' Response to Chemotherapy

May 10, 2007

Repeating Molecular Imaging Studies Provides Valuable Information for Better Patient Care, Say Researchers in May Journal of Nuclear Medicine

RESTON, Va.—An earlier indication of whether chemotherapy benefits non-small cell lung cancer patients—provided by positron emission tomography (PET) imaging—can guide doctors in offering them better care, according to researchers in the May Journal of Nuclear Medicine.

"Our study demonstrates that patients who respond to chemotherapy can be identified early in the course of their treatment, and these patients will generally exhibit prolonged overall survival," explained Claude Nahmias, professor of radiology and medicine at the University of Tennessee Medical Center in Knoxville. "Although we studied a relatively small number of patients—and our results should be interpreted with caution—it is clear that a repeat PET study with the radiotracer fluorodeoxyglucose (FDG) at the end of the first cycle of chemotherapy would allow the identification of those patients for whom the therapy was futile," he said. "The ability to provide an early indication of therapeutic response has the potential to improve patient care by identifying those patients who do not benefit from their current treatment," explained Nahmias. "Patients would benefit from either having chemotherapy and its associated toxic side effects stopped or going on to a different, and hopefully more adequate, therapeutic approach," added the co-author of "Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT."

Non-small cell lung cancer is the most common type of lung cancer, usually growing and spreading more slowly than small cell lung cancer. -Lung cancer is the second most common cancer and the most common cause of cancer-related death in both men and women in the United States. In 2007, about 213,380 new cases of lung cancer (both small cell and non-small cell) are expected in the United States, and about 160,390 people will die of this disease. For most patients with non-small cell lung cancer, current treatments do not cure the cancer.

"With non-small cell lung cancer—since the relatively modest increase in survival must be balanced against the toxicity of the chemotherapeutic treatment—the case for monitoring therapeutic response is especially compelling," said Nahmias. "To assess the response to chemotherapy in patients with advanced non-small cell lung cancer, all of the studies published thus far have evaluated the patients at one, or at most two, time points after the initiation of chemotherapy," said Nahmias. "In our study, we evaluated 15 patients weekly—for seven weeks—as they started their chemotherapy regiment. In spite of the persuasive findings of several studies investigating PET for monitoring response to cancer therapy, until now no published reports have clearly demonstrated that PET results were used to alter treatment," he noted.

PET is a powerful molecular imaging procedure that noninvasively demonstrates the function of organs and other tissues. When PET is used to image cancer, a radiopharmaceutical (such as FDG, which includes both a sugar and a radionuclide) is injected into a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is drawn in higher amounts to cancerous areas. PET scans show where FDG is by tracking the gamma rays given off by the radionuclide tagging the drug and producing three-dimensional images of their distribution within the body. PET scanning provides information about the body's chemistry, metabolic activity and body function.

"Our result—that PET studies one and three weeks after initiation of cancer therapy can predict success or failure of the therapy—should be validated in a larger study in which patients are enrolled with the intention of applying it in patient management," said Nahmias. He added, "I am forever grateful to all the patients who came back week after week to undergo our PET scans."

"Time Course of Early Response to Chemotherapy in Non-Small Cell Lung Cancer Patients With 18F-FDG PET/CT" appears in the May issue of the Journal of Nuclear Medicine, which is published by SNM, the world's largest molecular imaging and nuclear medicine society. Other co-authors are Wahid T. Hanna, Misty J. Long, Karl F. Hubner and David W. Townsend, departments of Medicine and Radiology, University of Tennessee, Knoxville, and Lindi M. Wahl, Department of Applied Mathematics, University of Western Ontario, London, Canada.

Society of Nuclear Medicine


Related Lung Cancer Current Events and Lung Cancer News Articles


Precision prevention of colorectal cancer
Precision medicine's public face is that of disease -- and better treatments for that disease through targeted therapies.

Plasma genotyping to predict treatment benefit in patients with NSCLC
The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.

Study shows how TRK-fusion lung cancer escapes LOXO-101, offering new treatment strategies
A University of Colorado Cancer Center study presented at the American Association for Cancer Research Annual Meeting 2016 pinpoints ways that cancer cells evolve to resist the drug LOXO-101, a kinase inhibitor of the TRK-fusion genes that drive a subset of cancers.

Precision medicine brings new hope to those with advanced urothelial cancer
Five of six patients with advanced metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.

Cancer research at Marshall University shows promise for combating deadly lung cancer
A study by researchers at Marshall University Joan C. Edwards School of Medicine has found that blocking the blood supply of small cell lung cancer tumors may help reduce their growth and delay the regrowth process after treatment. Small cell lung cancer is considered the most lethal of all lung cancers.

Nanoparticles deliver anticancer cluster bombs
Scientists have devised a triple-stage "cluster bomb" system for delivering the chemotherapy drug cisplatin, via tiny nanoparticles designed to break up when they reach a tumor.

New tool mines whole-exome sequencing data to match cancer with best drug
A University of Colorado Cancer study published today in the Journal of the American Medical Informatics Association (JAMIA) describes a new tool that interprets the raw data of whole exome tumor sequencing and then matches the cancer's unique genetics to FDA-approved targeted treatments.

Statement published on pairing smoking cessation with lung cancer screening
Researchers, including an associate professor from the Medical University of South Carolina Hollings Cancer Center, say smokers who go to a doctor to be screened for lung cancer should also be encouraged to quit smoking during their visit.

CRI researchers link absence of protein to liver tissue regeneration
Scientists at the Children's Medical Center Research Institute at UT Southwestern (CRI) report that inactivating a certain protein-coding gene promotes liver tissue regeneration in mammals.

Beyond DNA: TGen points the way to enhanced precision medicine with RNA sequencing
Uncovering the genetic makeup of patients using DNA sequencing has in recent years provided physicians and their patients with a greater understanding of how best to diagnose and treat the diseases that plague humanity. This is the essence of precision medicine.
More Lung Cancer Current Events and Lung Cancer News Articles

Non-Small Cell Lung Cancer: Across the Continuum of Care

Non-Small Cell Lung Cancer: Across the Continuum of Care
by Asante Communications, LLC


This Clinical Resource Tool is structured around consensus statements developed by the Non-Small Cell Lung Cancer (NSCLC) Working Group, a panel of oncologists with particular expertise in the multidimensional care of patients with advanced lung cancer. Using a modified Delphi process, the NSCLC Working Group has consolidated published evidence and expert clinical experience on critical issues pertaining to the comprehensive assessment of patients with advanced NSCLC, formulation of appropriate treatment regimens, implementation of maintenance therapy, and therapeutic alliances among pathologists, oncologists, and pulmonologists. The consensus statements and accompanying resources are intended as a practical companion to current guidelines, helping clinicians individualize best-practice...

Lung Cancer Causes, Symptoms,  Stages & Treatment Guide: Cure Lung Cancer With  A Positive Outlook

Lung Cancer Causes, Symptoms, Stages & Treatment Guide: Cure Lung Cancer With A Positive Outlook
by Danielle Dixon


This book contains proven steps and strategies on how to prevent, treat and fight cancer.

Cancer has long been closely associated with death, low quality of life, and financial difficulties. With all the complications it causes, lives it takes, and people it subjects to suffering, cancer is definitely a difficult disease.

Lung cancer is one of the leading causes of cancer deaths worldwide. Different risk factors have been attributed to its development- with genetics and environmental influences playing a major role. The diversity of its causes makes its treatment all the more difficult, which makes identification of causes essential to its management. The recognition of symptoms and diagnosis early in the course of the disease most frequently leads to good...

Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope

Bonnie J. Addario Navigating Lung Cancer 360 Degrees of Hope
by Bonnie J. Addario (Author), MD, PhD, Shane P. Dormady (Author), RN, MSN, CPHQ, Eileen Johnson (Author), RN, MBA, Alicia Sable-Hunt (Author), Danielle Hicks (Editor), MD, Paul Hesketh (Editor), MD, Robert Sinha (Editor), MD, PhD, D. Ross Camidge (Editor), MD, Elizabeth A. David (Editor), MD, Lisa Boohar (Editor), MD, David R. Gandara (Editor), PhD, Guneet Walia (Editor), Inc., Sheila Von Driska?White Space (Editor)


Navigating Lung Cancer 360 Degrees of Hope is the most comprehensive guidebook for surviving lung cancer. Inside each latest edition you will get the most up-to-date navigation tools on the diagnosis process, lung cancer staging, treatment options, clinical trials, living with lung cancer, financing your care, hope for surviving lung cancer, and more. Written by survivor Bonnie J. Addario and the leading experts in lung cancer with one goal: to turn lung cancer into a manageable and survival disease.

How to Survive Lung Cancer - A Practical 12-Step Plan

How to Survive Lung Cancer - A Practical 12-Step Plan
by Michael Lloyd (Author)


Written by a lung cancer survivor who understands what it takes to beat the odds, this book offers unparalleled hope and direction for anyone facing this illness. It is filled with specific exercises and techniques to promote healing and reverse side effects by taking a pro-active approach in helping to restore your mind, body and spirit to an optimum state of health. Endorsed by a Lung Cancer Specialist and Associate Professor at Harvard Medical School, this book combines what the doctors tell you with critical information they don't tell you. Visit www.SurviveLungCancer.com for chapter summaries.

Johns Hopkins Patients' Guide To Lung Cancer

Johns Hopkins Patients' Guide To Lung Cancer
by Justin F. Klamerus (Author), Julie R. Brahmer (Author), David S Ettinger (Author)


Johns Hopkins Patients' Guide to Lung Cancer is a concise, easy-to-follow “how to” guide that puts you on the path to wellness by explaining lung cancer treatment from start to finish. It guides you through the overwhelming maze of treatment decisions, simplifies the complicated schedule that lies ahead, and performs the task of putting together your plan of care in layman's terms. Empower yourself with accurate, understandable information that will give you the ability to confidently participate in the decision making about your care and treatment.

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions

You Can Beat Lung Cancer: Using Alternative/Integrative Interventions
by Carl O. Helvie (Author)


Can you overcome lung cancer without harsh chemicals, surgery and debilitation? Are alternative interventions effective? Why do conventional physicians not use them? Can you prevent cancer recurrences and live into old age without chronic diseases and prescribed medications? This book answers these and other questions.

This is one of the most comprehensive books available on alternative treatments for lung cancer. It explains the treatments used successfully by a health professional/cancer survivor of 36 years and by some of the leading medical and health practitioners currently in the field. G. Edward Griffin, Author of World Without Cancer, The Politics of Cancer Therapy, and other books and films. Recipient of the Telly Award for Excellence in Television Production. President of...

100 Questions  &  Answers About Lung Cancer (100 Questions and Answers)

100 Questions & Answers About Lung Cancer (100 Questions and Answers)
by Joan H. Schiller (Author), Amy Cipau (Author)


EMPOWER YOURSELF! No one with lung cancer needs to be alone in their fight against this disease. 100 Questions & Answers About Lung Cancer, Third Edition, guides patients and their families through diagnosis, treatment and survivorship. Providing both the doctor’s and patient’s point of view, this book is a complete guide to understanding treatment options, post-treatment quality of life, sources of support, and much more. Through 100 Questions & Answers About Lung Cancer, Third Edition, expert authors use their experiences with patients to provide support and hope to the tens of thousands of people coping with lung cancer.

Living With A Diagnosis Of Lung Cancer

Living With A Diagnosis Of Lung Cancer
by Joan Schiller MD (Author)


"Living With a Diagnosis of Lung Cancer” is an easy-to-understand booklet written to help lung cancer patients understand their diagnosis and their options as they face the disease. Lung cancer claims more lives than breast, prostate, and colon cancers combined. In fact, over 288,000 people are diagnosed each year in the U.S. People with lung cancer often are told, "Get your affairs in order." But, there is hope for those diagnosed with lung cancer. Thanks to research advances, there are options available to patients diagnosed regardless of the stage of the disease. Much progress is being made with new treatments being developed and tested each day. This valued resource will help you know what questions to ask of your medical team and can help you understand your treatments...

Anticancer: A New Way of Life

Anticancer: A New Way of Life
by David Servan-Schreiber (Author)


Anticancer has been a bestselling phenomenon since Viking first published it in fall 2008. Now, a new edition addresses current developments in cancer research and offers more tips on how people living with cancer can fight it and how healthy people can prevent it. The new edition of Anticancer includes:

• The latest research on anticancer foods, including new alternatives to sugar and cautions about some that are now on the market
• New information about how vitamin D strengthens the immune system
• Warnings about common food contaminants that have recently been proven to contribute to cancer progression
• A new chapter on mind-body approaches to stress reduction, with recent studies that show how our reactions to stress can interfere with...

When Breath Becomes Air

When Breath Becomes Air
by Paul Kalanithi (Author), Abraham Verghese (Foreword)


#1 NEW YORK TIMES BESTSELLER • For readers of Atul Gawande, Andrew Solomon, and Anne Lamott, a profoundly moving, exquisitely observed memoir by a young neurosurgeon faced with a terminal cancer diagnosis who attempts to answer the question What makes a life worth living?

At the age of thirty-six, on the verge of completing a decade’s worth of training as a neurosurgeon, Paul Kalanithi was diagnosed with stage IV lung cancer. One day he was a doctor treating the dying, and the next he was a patient struggling to live. And just like that, the future he and his wife had imagined evaporated. When Breath Becomes Air chronicles Kalanithi’s transformation from a naïve medical student “possessed,” as he wrote, “by the question of what, given that all organisms die, makes a...

© 2016 BrightSurf.com